已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.

2019年冠状病毒病(COVID-19) 2019-20冠状病毒爆发 2型糖尿病 严重急性呼吸综合征冠状病毒2型(SARS-CoV-2) 临床试验 临床终点
作者
Mikhail Kosiborod,Russell Esterline,Remo H.M. Furtado,Jan Oscarsson,Samvel B. Gasparyan,Gary G. Koch,Felipe Martinez,Omar Mukhtar,Subodh Verma,Vijay K. Chopra,Joan Buenconsejo,Anna Maria Langkilde,Philip Ambery,Fengming Tang,Kensey Gosch,Sheryl L. Windsor,Emily E Akin,Ronaldo V P Soares,Diogo D.F. Moia,Matthew Aboudara,Conrado R. Hoffmann Filho,Audes D. M. Feitosa,Alberto Fonseca,Vishnu Garla,Robert Gordon,Ali Javaheri,Cristiano P Jaeger,Paulo Leães,Michael E. Nassif,Michael Pursley,Fabio Serra Silveira,Weimar Kunz Sebba Barroso,José Roberto Lazcano Soto,Lilia Nigro Maia,Otavio Berwanger
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:9 (9): 586-594 被引量:23
标识
DOI:10.1016/s2213-8587(21)00180-7
摘要

Summary Background COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has significant protective benefits for the heart and kidney. We aimed to see whether this agent might provide organ protection in patients with COVID-19 by affecting processes dysregulated during acute illness. Methods DARE-19 was a randomised, double-blind, placebo-controlled trial of patients hospitalised with COVID-19 and with at least one cardiometabolic risk factor (ie, hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease). Patients critically ill at screening were excluded. Patients were randomly assigned 1:1 to dapagliflozin (10 mg daily orally) or matched placebo for 30 days. Dual primary outcomes were assessed in the intention-to-treat population: the outcome of prevention (time to new or worsened organ dysfunction or death), and the hierarchial composite outcome of recovery (change in clinical status by day 30). Safety outcomes, in patients who received at least one study medication dose, included serious adverse events, adverse events leading to discontinuation, and adverse events of interest. This study is registered with ClinicalTrials.gov , NCT04350593 . Findings Between April 22, 2020 and Jan 1, 2021, 1250 patients were randomly assigned with 625 in each group. The primary composite outcome of prevention showed organ dysfunction or death occurred in 70 patients (11·2%) in the dapagliflozin group, and 86 (13·8%) in the placebo group (hazard ratio [HR] 0·80, 95% CI 0·58–1·10; p=0·17). For the primary outcome of recovery, 547 patients (87·5%) in the dapagliflozin group and 532 (85·1%) in the placebo group showed clinical status improvement, although this was not statistically significant (win ratio 1·09, 95% CI 0·97–1·22; p=0·14). There were 41 deaths (6·6%) in the dapagliflozin group, and 54 (8·6%) in the placebo group (HR 0·77, 95% CI 0·52–1·16). Serious adverse events were reported in 65 (10·6%) of 613 patients treated with dapagliflozin and in 82 (13·3%) of 616 patients given the placebo. Interpretation In patients with cardiometabolic risk factors who were hospitalised with COVID-19, treatment with dapagliflozin did not result in a statistically significant risk reduction in organ dysfunction or death, or improvement in clinical recovery, but was well tolerated. Funding AstraZeneca.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
人老多情发布了新的文献求助30
刚刚
听寒完成签到 ,获得积分10
刚刚
学霸业的应助被科研通管家采纳,获得10
2秒前
2秒前
脑洞疼的应助被科研通管家采纳,获得10
2秒前
学霸业的应助被科研通管家采纳,获得200
2秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
2秒前
彭于晏的应助被科研通管家采纳,获得10
2秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
2秒前
在水一方的应助被科研通管家采纳,获得10
2秒前
3秒前
3秒前
3秒前
日尧完成签到,获得积分10
4秒前
4秒前
简单的皮皮虾完成签到 ,获得积分10
4秒前
勤劳的瑀发布了新的文献求助10
6秒前
拼搏的水桃完成签到,获得积分10
7秒前
8秒前
sun完成签到,获得积分10
9秒前
9秒前
可靠追命发布了新的文献求助10
11秒前
北陌完成签到 ,获得积分10
12秒前
Yuther完成签到 ,获得积分10
13秒前
15秒前
心灵美的小伙完成签到,获得积分10
15秒前
热心的凝云完成签到 ,获得积分10
16秒前
言宴发布了新的文献求助10
19秒前
李志侠完成签到 ,获得积分10
19秒前
Hello的应助被心灵美的小伙采纳,获得10
20秒前
XZC完成签到 ,获得积分10
20秒前
谦让的代桃完成签到 ,获得积分10
21秒前
宁静致远完成签到,获得积分10
22秒前
鲜艳的狂想完成签到 ,获得积分10
22秒前
Lucas的应助被浮云采纳,获得10
23秒前
小蘑菇的应助被u459150采纳,获得10
23秒前
战国完成签到 ,获得积分10
27秒前
27秒前
英俊的铭的应助被成就煎蛋采纳,获得30
29秒前
liu完成签到,获得积分10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194853
求助须知:如何正确求助?哪些是违规求助? 9580564
关于积分的说明 21871986
捐赠科研通 7794485
什么是DOI,文献DOI怎么找? 3437769
关于科研通互助平台的介绍 2561095
邀请新用户注册赠送积分活动 2484486